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INTRODUCTION
Uterine leiomyosarcoma is a rare but aggressive uterine neoplasm associated with poor outcomes. Federation of Gynecology and Obstetrics (FIGO) stage and tumor grade have been found to be the most important prognostic factors determining survival of these patients [1] [2] [3] , although age at diagnosis, tumor size, mitotic rate, lymphovascular invasion, menopausal status, and parity have also been identified as prognostic factors [1] [2] [3] [4] [5] [6] . In 2008, FIGO revised their staging system for uterine leiomyosarcomas and separated it as a distinct entity [7] . The previous 1988 FIGO classification [8] employed criteria based on endometrial carcinoma despite the differences in the biological behaviour of uterine leiomyosarcomas and endometrial carcinomas, such as the propensity for uterine leiomyosarcomas to spread hematogenously rather via the lymphatic system.
Because tumor staging forms the basis for comparisons of data across institutions, influences patient treatment decision, and determines prognosis, it is important to understand to how and to what extent patients will be reclassified under the revised 2008 FIGO staging system. However, to our best knowledge, there are currently no published studies that directly compare the 1988 and 2008 revised FIGO staging systems, although two studies have compared FIGO to the AJCC soft tissue sarcoma staging system [9 -11] . In both of these analyses, neither AJCC nor the revised FIGO were able to adequately classify patients with uterine leiomyosarcomas into clinically meaningful and nonoverlapping stages. Large proportions of cases (48% and 54%) were still classified as stage I disease, with very few as stage II and III disease.
The aim of our study was to compare and contrast the performance of the 1988 and revised 2008 FIGO staging systems in our cohort of Asian patients, which was predominantly comprised of Chinese, Malay, and Indian patients. We sought to determine the proportion of individuals who would undergo stage shift under the revised FIGO staging system that is specific for uterine leiomyosarcomas and to determine the stage distribution of patients under the new system. To date, prognostic factors in uterine leiomyosarcomas have been evaluated mainly in Western cohorts, with an underrepresentation of Asian patients. We therefore sought to clarify the role of traditional prognostic factors such as age, grade, and use of adjuvant chemotherapy in our Asian cohort, as well as their abilities to risk discriminate patients with early stage I disease.
PATIENTS AND METHODS

Case Selection
After approval by the institutional review boards of the National Cancer Centre Singapore and KK Women's and Children's Hospital Singapore, prospectively maintained gynecologic oncology tumor databases were used to identify all patients with uterine leiomyosarcomas who had underwent tumor board histopathological tumor board review and treatment at the centers from 1974 to 2010. Study inclusion criteria required the pathological diagnosis of uterine leiomyosarcomas to have been made by an institutional pathologist. Both institutions used the World Health Organization criteria to establish the diagnosis of uterine leiomyosarcomas. Uterine tumors exhibiting smooth muscle differentiation were diagnosed as uterine leiomyosarcomas if they showed the presence of at least two of the following three features: moderate to severe nuclear atypia, mitotic index Ն10 mitotic figures per 10 highpower fields, and/or tumor cell necrosis.
For the analysis, individual patient case notes were retrieved and data manually culled for age at diagnosis, ethnicity, Eastern Cooperative Oncology Group performance status, comorbidities (diabetes mellitus, hyperlipidemia, ischemic heart disease), prior tamoxifen exposure, tumor size, grade, mitotic count, depth of invasion, lymphovascular invasion, serosal involvement, lymph node metastasis, surgical margin involvement, type of surgery (hysterectomy, bilateral salpingooophorectomy, pelvic lymph node dissection), adjuvant radiation therapy, adjuvant chemotherapy, the date of initial diagnosis, recurrence, and death. Death outcomes were supplemented by vital data obtained from the National Death Registry.
Tumor staging was retrospectively assessed using the 1998 FIGO and 2008 modified FIGO criteria. Patients with atypical leiomyomas, sarcomas of uncertain malignant potential, and sarcomas centered in the pelvis, broad ligament, or vagina were excluded.
Although three-tiered or four-tiered grading systems have been applied by some pathologists for the grading of peripheral soft tissue sarcomas, the departments of pathology at both institutions did not employ a formal routine grading system or protocol for grading uterine leiomyosarcomas. Many reports of uterine leiomyosarcomas did not include tumor grade because it was assumed that all uterine leiomyosarcomas were high-grade lesions; low-grade tumors of uncertain malignant potential were classified as sarcomas of uncertain malignant potential.
Statistical Analysis
Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. Patients who were alive or lost to follow-up at the time of analysis were censored at the date of last follow-up. The Kaplan-Meier method was used to estimate OS distribution, and the log-rank test was applied to test the differences between OS curves.
Cox proportional hazard models were fitted to estimate hazard ratios to assess the association of various factors with OS. The proportional hazards assumption underlying the Cox model was verified for each fitted model using Schoenfeld residuals. The discriminative ability of a fitted Cox model to predict OS was evaluated using Harrell's concordance index (cindex) for censored data [12] . The c-index represents the probability of concordance between predicted and observed survival such that, when two patients are randomly selected, the one with the higher predicted survival is the one who survived longer; values range from 0.5 (random prediction) to 1 (perfect ability to discriminate). A two-sided p value of Ͻ.05 was considered to be statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
A total of 110 cases of uterine leiomyosarcomas were reviewed and data from 88 patients who met the inclusion criteria were analyzed. The median age of patients in our study was 51 years (range: 32-73 years) and the median follow-up was 28.2 months. In all, 74% of patients were Chinese, 11% were Malay, 7% were Indian, and 8% had other nationalities. The majority of patients had tumor size Ն5 cm (81%) and highgrade tumors (80%). Hysterectomy with bilateral salpingooophorectomy was performed in 88% of patients and adjuvant radiation was administered in 22% of patients. Patient and tumor characteristics are summarized in Table 1 . system, nine patients (10.2%) were downstaged and none were upstaged under the revised system ( Table 2 ). The median OS of all patients was 47.3 months (Table 3 ). There was a significant difference in OS between the four stages under both the 1988 and revised 2008 FIGO staging systems (Fig. 1A, B) . However, the revised system did not show a significant improvement in the ability to discriminate the risk of death of patients in the different stages, with a c-index of 0.71 and 0.70 for the 1988 and revised 2008 FIGO systems, respectively.
Comparison of FIGO Staging Systems
Prognostic Factors
There was a significant difference in the OS of all patients by age group (p ϭ .004), tumor grade (p ϭ .001), tumor size groups (Ͻ5 cm, 5.1-10 cm, and Ͼ10 cm; p ϭ .001), and the presence of lymphovascular invasion (p ϭ .014; Fig. 2 ). In comparison, receipt of adjuvant chemotherapy did not lead to improved OS (p ϭ .695). Within each new FIGO stage and age group strata, there was also no significant association between adjuvant chemo and OS.
Univariate Cox Regression Analysis for Stage I Disease
For patients with stage I disease under the revised 2008 FIGO staging system, advanced age at diagnosis was a significant adverse prognostic factor (p ϭ .003). When analyzed according to age, each decade of advancing age (Ͻ40 years, 40 -49 www.TheOncologist.com years, 50 -59 years, and Ն60 years) was associated with a poorer survival outcome.
Larger tumor size (Յ5 cm, Ͼ5 but Ͻ10 cm, and Ն10 cm) was significantly associated with an inferior OS (p ϭ .022). Within the revised Stage IB subgroup (i.e., tumors Ͼ5 cm), survival was inferior for tumors Ն10 cm as compared with tumors Ͼ5 cm but Յ10 cm. High tumor grade and the presence of lymphovascular invasion were also significantly associated with inferior OS. The hazard ratios for each factor are summarized in Table 4 .
Multivariate Cox Regression Analysis for Stage I Disease
Only 25 deaths were observed among all the stage I patients under the revised 2008 FIGO staging system. To avoid model overfitting, two multivariate Cox regression models were performed, which examined the association of the revised 2008 FIGO staging system to tumor size, presence of lymphovascular invasion, and age at diagnosis. The covariates included in the first model were revised FIGO staging system, lymphovascular invasion, and age of diagnosis; the covariates in the second model were tumor size, lymphovascular invasion, and age at diagnosis. Tumor grade was not included in the multivariate analysis due to the high proportion of patients with unknown tumor grade in the dataset. Inclusion of tumor grade in the multivariate analysis would lead to the study cohort to be comprised of at most 13 deaths and consequently a fitted multivariate Cox model based on the sample is unlikely to be reliable [12] .
After adjusting for lymphovascular invasion, tumor size and age at diagnosis were no longer significantly associated with OS in both models (Table 5) . Thus, lymphovascular invasion was an independent prognostic factor based on multivariate analysis. The c-index of the Cox model based on lymphovascular invasion for stage I patients was 0.66, which was higher than the c-index (0.62) based on the revised FIGO staging system for these patients. [10] , the concordance index for OS under the revised 2008 FIGO staging system was 0.62-a figure lower than in our series. In their study, a disproportionate number of cases (54.3%) were also classified as stage I disease, with 22.4% of cases of stage IV disease; similarly, there were very few patients with stage II and III disease (5.5% and 17.8%, respectively). In the study by Raut et al. [11] , patient distribution was similarly uneven across the stage group, with 48%, 5%, 16%, and 23% of individuals in stages I, II, III, and IV, respectively (8% had missing data).
Analysis as a Single Stage Group for Stage II and III Disease
Because of this uneven stage distribution of patients in our cohort and the paucity of stage II and III disease, we undertook exploratory analysis to further modify the revised FIGO staging system by collapsing stage II and III disease into a single stage group (designated mStage III), while reclassifying stage This appeared to improve stage distribution while providing a slight improvement in the c-index from 0.70 to 0.75. Even though the magnitude of improvement of the c-index was modest, we feel there may be merit to considering this alternative staging system. Firstly, it would result in a more even spread of patient frequencies across the various stages. Secondly, it would allow for easier incorporation of molecular pathologic prognostic factors into a staging system based on an easily quantifiable parameter (tumor size) in early stage disease. This would allow for relatively straightforward interaction testing between molecular features and clinical and pathological factors (i.e., grade, lymphovascular invasion). Tumor size has been shown to be an independent prognostic factor in many studies. In our analysis of the FIGO stage I patient cohort, the c-index based on a three-tier system (i.e., Ͻ5 cm, Ͼ5 but Ͻ10 cm, and Ͼ10 cm) also performed better than the stage IA and IB FIGO system (data not shown). In advanced stage disease, molecular pathology may be correlated with a tumor's potential to invade locally (stage III) or metastasize (stage IV). However, our analysis is exploratory and will need reassessment and validation. To date, nearly all of the published survival outcome data for uterine leiomyosarcomas have been from Western case series [13] [14] [15] [16] [17] [18] . Our study represents one of the largest series of uterine leiomyosarcomas in Asian patients, and we sought to identify prognostic classifiers for uterine leiomyosarcomas, in particular for stage I disease. Although age at diagnosis, tumor size, tumor grade, and lymphovascular invasion were significant prognostic factors on univariate analysis, only lymphovascular invasion remained significant after adjustment for other factors (although age and tumor size neared statistical significance). It has been repeated that a good staging system is one that aids the clinician in planning treatment, provides an indication of prognosis, facilitates the exchange of information between treatment centers, and allows meaningful comparisons of treatment outcomes. A better FIGO staging system should thus have three basic characteristics, such as validity, reliability, and practicality [19] . In this regard, we sought to compare the stage-specific survival rates under the revised FIGO system with data reported from other cohorts. Although the median OS for stage I disease was substantially higher in our cohort (135.8 months; 95% confidence interval [CI]: 47.3 months to an undefined upper limit) compared with Raut et al. (69.2 months; 95% CI: 51.6 -90.3 months), the median OS times in stage II, III, and IV disease were markedly inferior. For example, the median OS times in our cohort versus Raut et al. were 14.8 months (95% CI: 6.6 months to an undefined upper limit) versus 88.8 months (95% CI: 22.1-147.7 months) for stage II disease, 11.4 months (95% CI: 2.1 months to an undefined upper limit) versus 50.1 months (95% CI: 28.7-62.7 months) for stage III disease, and 7.9 months (95% CI: 3.9 -20.6 months) versus 23.5 months (95% CI: 17.0 -31.8 months) for stage IV disease, respectively. Although these differences may be attributed to differences in follow-up (26.5 months median follow-up in Raut et al.) or various biological, ethnic, or treatment differences between the two populations, stage for stage, such wide variations in OS deserve attention and further evaluation.
Our study has shown that the revised 2008 FIGO staging system for uterine leiomyosarcomas does not represent an improvement from the 1988 system that had been based on uterine endometrial carcinomas. Although 10% of patients were reclassified (downstaged) under the revised FIGO system, the ability to accurately assign prognosis based on stage as measured by the concordance index was virtually unchanged, so a better system is needed.
The AJCC staging system for soft tissue sarcomas has been evaluated in uterine leiomyosarcomas but was found to have limited utility in classifying patients into four meaningful, nonoverlapping stages that could accurately predict progressionfree survival and OS [11] . Although some experts sought to overcome these limitations by eliminating staging in favor of individualized patient nomograms [20] , this strategy fails to provide a platform that is accessible to doctors and patients and allows straightforward comparisons of data. We feel that a staging system based on size and anatomical extent of tumor spread still has relevance and utility today; it recapitulates the patterns of growth and spread of the tumor over time, and surgery (en-bloc removal) still remains the cornerstone of uterine leiomyosarcomas therapy. However, any future revision of FIGO uterine leiomyosarcoma staging should consider the use of risk scoring systems incorporating factors such as lymphovascular invasion, grade, size, and age to fine-tune prognosis in each stage. Such a staging system would have the advantage of reflecting tumor heterogeneity while preserving simplicity. A risk scoring system would not only allow assessment of a very wide range of risk factors, but would also admit new or emerging risk factors without overburdening the staging system with unmanageable complexity, errors, or frequent changes. Within such a framework, prognostic and predictive molecular markers may also be more readily tested for interactions against other risk factors. Tumor staging has been one of the most important innovations in cancer management and represents the foundation upon which treatment modalities are assigned and progress evaluated. As oncology embraces a future that is increasingly molecular driven, a valid and reliable clinical staging system will become even more relevant and important. In the past, progress for uterine sarcomas had been impeded because of the diversity and rarity of these tumors. Future development of the field will therefore be dependent on the strenuous efforts of researchers to forge partnerships to pool data for improved statistical power and to coordinate biospecimen processing so as to better classify, prognosticate, and validate results for this rare disease.
